XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Revenues
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended March 31,
20232022
U.S.ROWTotalU.S.ROWTotal
Prolia$623 $304 $927 $582 $270 $852 
ENBREL564 15 579 843 19 862 
XGEVA384 152 536 368 134 502 
Otezla294 98 392 350 101 451 
Repatha197 191 388 165 164 329 
Nplate246 116 362 156 110 266 
KYPROLIS234 124 358 196 91 287 
Aranesp115 240 355 137 221 358 
EVENITY164 90 254 110 60 170 
Other products(1)
1,154 541 1,695 1,130 524 1,654 
Total product sales(2)
$3,975 $1,871 5,846 $4,037 $1,694 5,731 
Other revenues259 507 
Total revenues$6,105 $6,238 
____________
(1)    Consists of product sales of our non-principal products, as well as our Bergamo and Gensenta subsidiaries.
(2)    Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2023 and 2022.